Stockholm March 7th, 2022
BioLamina further Strengthens Leadership by appointing Pia van der Zee as Chief Commercial Officer
BioLamina is in its expansive phase. In the past decade, our flagship products, human recombinant laminin proteins (Biolaminin®) have become the renowned cell culture substrates in both basic research and for companies within regenerative medicine. To further expand our business globally, BioLamina has recruited Pia van der Zee as its new Chief Commercial Officer.
Pia van der Zee has over two decades’ experience in the global life science industry and has held commercial positions in business development, sales, and marketing. She holds a Master of Chemical Engineering from DTU – the Technical University of Denmark and equivalent of a Bachelor in Business Administration from Copenhagen Business School. She started her career as an Application Scientist at Novozymes (biological solutions- industrial enzymes, microorganisms, and biopharmaceutical ingredients). She found her true calling in commercial operations, as Area Sales Manager for Thermo Fisher Scientific (supplier of scientific instrumentation, reagents and consumables, and software services). Since then, she has held leading commercial positions in companies including ChemoMetec (automated cell counters and analysis equipment), Agilent Technologies (laboratory solutions), and Pharmacosmos (medicines for treating iron deficiency anaemia in humans and animals). Most recently Pia was Vice President of Marketing at 2cureX (Invitro Diagnostic tests involving 3D microtumors for cancer therapy selection).
Veronica Byfield Sköld, CEO of BioLamina: “Today BioLamina foresees significant global business opportunities. This growth aligns perfectly with Pia’s global commercial experience and proven leadership skills. Throughout her career, Pia has built a strong platform within sales leadership, marketing, and product management. She has worked in larger corporations as well as startup and scale-up organizations. In addition to her strong skills in the commercial field, she has a strong entrepreneurial profile and brings a lot of energy and passion, which I believe will be an excellent fit with our team. We are extremely pleased to welcome Pia to BioLamina”.
Pia van der Zee: “Over the years, I have been fortunate enough to make new and innovative life science solutions available to scientists around the world in a wide range of companies and positions. I am delighted to have found the next rising star. BioLamina is in a strong growth phase, and I look forward to helping the team build on all the hard work they have done over the years to reach this position. Our ambition? To make our Biolaminin® the cell culture substrate of choice for scientists around the world.”
For more information, please contact:
Veronica Byfield Sköld, CEO
Phone: +46 730 733 933
Press images: Photo gallery – BioLamina
BioLamina AB is a Swedish biotechnology company built on a scientific foundation with a legacy in matrix biology and cell culture-based research. Our flagship products, our biorelevant human recombinant laminin isoforms, Biolaminin®, are defined cell culture matrices that successfully imitate the natural, cell-specific cell-matrix interaction in the cell culture dish, allowing the cells to thrive and maintain their function. Our products are a powerful resource for scientists working with stem cells and primary cells both within basic research as well as in regenerative medicine companies with a focus on cell therapy applications.
We think you might be interested in…
Management Team A desire to contribute to the stem cell community The highly educated, international
Biolamina matrices enable scientific progress Whether for disease modeling or preparing cells for cl
Newsroom BioLamina AB sets the stage for US expansion by opening office in Boston The new location w